Biosimilar Insulins Satisfy EMA’s CHMP
NovoMix And Actrapid Rivals From Sanofi And Baxter Endorsed By Agency
The EMA’s CHMP has issued positive opinions for two insulin biosimilars: Sanofi’s insulin aspart rival to NovoMix and Baxter’s insulin human (rDNA) version of Actrapid. At the same time, the CHMP has confirmed its recommendation to refuse marketing authorization for the Ipique ophthalmic version of bevacizumab.
